1. Aim/Purpose of this Guideline

1.1. Effective analgesia is crucial to patient outcome after major surgery to ensure comfort, mobilisation and decreased risk of potential post-operative complications such as DVT and chest infection.

1.2. As surgical techniques change and length of inpatient stay decreases, it is important to offer a safe, flexible method of analgesia which may be delivered in both a hospital and community environment if necessary.

1.3. Blockade of pain impulses by local anaesthetic has been shown to give effective pain relief and to decrease other methods of analgesia required – eg opioids with consequent decrease of side effects.

1.4. This document outlines the potential and actual use of Local Anaesthetic within RCHT and the precautions and care required.

1.5. Purpose:

   • To ensure that there is a common understanding of use of local anaesthetic to ensure safe delivery of care by all health professionals involved in the care of post-operative patients.
   • To ensure that the necessary knowledge and competencies are practised throughout the Trust for delivery - care of the patient, knowledge of the drugs, potential side effects and use of any equipment delivering infusions.
   • To ensure that appropriate training in line with RCHT policies should be undertaken by those using the equipment or delivering bolus injections.

2. The Guidance

2.1. Roles and Responsibilities

2.1.1. Medical Staff

   2.1.1.1. Local anaesthetic blocks are usually delivered by medical staff competent in the technique of nerve blockade either as a single injection or catheter placement for continuous infusion.
2.1.1.2. It would be expected that they have the appropriate knowledge of full aseptic technique, intravenous cannulation and resuscitation skills as per RCHT guidelines, as well as knowledge of the relevant anatomy and the drugs being used, together with treatment of side effects.
2.1.2. **Medical Prescribers**

2.1.2.1. Should be able to prescribe clearly in line with guidelines stating:

- the total dosage in mg/24 hours and
- the volume and
- the concentration to be delivered together with
- administration times e.g. hourly or as a timed bolus dose.

2.1.2.2. Knowledge of safe total dose per 24 hours period is essential together with the necessary observations required and treatment of side effects.

2.1.2.3. Prescribing teams should review all prescriptions on a daily basis together with the pain scores and analgesic needs of the patient.

2.1.3. **Nursing Staff**

2.1.3.1. Nursing staff should be responsible for the timely delivery of analgesia as prescribed – this may include changing an infusion

2.1.3.2. Nursing staff are responsible for the ongoing monitoring of pain scores on rest and movement, motor power and sensation and signs of local anaesthetic toxicity as well as the vital monitoring signs of pulse and respiratory rates, oxygen saturation and BP.

2.1.3.3. Adverse reactions should be reported to the prescriber or doctor on the ward and further instruction on administration received.

2.1.3.4. Nurses should contact the Acute Pain Team for further advice if required bleep 3233 during the working week or the anaesthetist on call out of hours. (1st on call Bleep 2746, Senior Anaesthetic Trainee 3513)

2.1.4. **Pharmacists**

As part of the regular monitoring, pharmacists should ensure adherence to guidelines with regards to appropriateness, accuracy, safety and clarity of prescribing.

2.2. **Physiology of Nerve Conduction and Mechanism of Local Anaesthetics**

2.2.1. Pain occurs because of stimulation of nerve receptors and the ongoing transmission of this stimulation via nerve fibres to the spinal cord and brain where it is registered as an unpleasant physical and emotional experience and will cause both physiological and subjective responses in a patient.
2.2.2. A selection of receptors in the skin and subcutaneous tissue can detect pain whilst the onward transmission occurs via the smaller nerve fibres.

2.2.3. There are a variety of nerve fibres with different size and function to include movement, sensation of heat and cold, touch and position as well as the sympathetic or autonomic nervous system which controls parameters such as dilation and constriction of blood vessels.

<table>
<thead>
<tr>
<th>Table 1</th>
<th>Classification of nerve Fibres</th>
</tr>
</thead>
<tbody>
<tr>
<td>Class</td>
<td>Size</td>
</tr>
<tr>
<td>A – alpha</td>
<td>largest</td>
</tr>
<tr>
<td>A – beta</td>
<td>▼</td>
</tr>
<tr>
<td>A- gamma</td>
<td>▼</td>
</tr>
<tr>
<td>B</td>
<td>▼</td>
</tr>
<tr>
<td>C</td>
<td>smallest</td>
</tr>
</tbody>
</table>

2.2.4. The smaller fibres do not have a protective sheath of myelin and therefore are more easily blocked than the larger ones. The dose of local anaesthetic which is required to block a larger nerve fibre for motor power or sensation will inevitably block the smaller fibres as well. The onset and recovery of nerve block, for example, for movement is usually preceded by the smaller nerve fibres often demonstrated by a change in sensation and blood pressure before motor power returns.

2.2.5. Once stimulated the nerve undergoes a process known as depolarisation to transmit the impulse – this is caused by a variety of changes within the nerve involving sodium channels in the nerve membrane which open and allow sodium into the cell. Local anaesthetics block the sodium channels and hence ongoing transmission of painful stimuli.

2.2.6. Because nerve fibres connect via synapses throughout the body to reach the spinal cord and brain, local anaesthetics can be applied:

- Peripherally – to block skin/subcutaneous receptors
- To a particular nerve or nerve plexus
- To the epidural or spinal nerves

2.2.7. This document offers guidance to the use of peripheral and nerve plexus local anaesthetic blocks requiring either a bolus dose or infusion
technique via a catheter excluding epidural or spinal use which is covered in a specific document.

2.2.8. Protocols for specific more common techniques will be included as appendices:

- Subcutaneous infusions
- Rectus Sheath/TAPS
- Nerve plexus blocks
- Sub Pectoral Catheters

2.3. Definition

2.3.1. A peripheral nerve is one which lies outside of the central neural canal (i.e. excludes epidural and spinal blockade).

2.3.2. A continuous peripheral nerve blockade is achieved by placing a fine catheter close to a nerve or nerve receptors and infusing a solution of local anaesthetic either at an hourly rate or as prescribed bolus doses. The presence of the catheter allows the block to continue for a number of days post-surgery, thereby improving patient analgesia, and lessening the need for more invasive blocks or strong opiates.

2.3.3. Infusion rates will depend on the area being blocked and the expected rate of absorption from that area (depending on vascularity).

2.3.4. More than one nerve may supply an area and therefore this technique usually requires adjunct analgesia to avoid discomfort. Where there is major surgery which requires strong opioids, the total dose and risk of opioid side effects will be less.

2.4. Clinical Indications

Table 2 – Indications for peripheral nerve blockade

- Patients expected to experience pain after surgery
- As an alternative to epidural analgesia
- As part of a multimodal approach to analgesia to decrease opiate requirements, avoid urinary catheterisation and potentiate more rapid mobilisation

2.5. Contraindications

Table 3 – Contraindications for peripheral nerve blockade

- Patient refusal
- Previous adverse effects with local anaesthetics
- Superficial infection at site of potential insertion
- Inadequate knowledge to perform block
- Inadequately experienced ward staff to care for patient post operatively
- Bleeding disorders
2.6. Guidelines for Catheter Insertion

2.6.1. Catheters should only be placed adjacent to nerves by experienced practitioners with knowledge of the relevant anatomy and an acceptable method for nerve location - electrical stimulation or ultrasound.

2.6.2. The patient should have had prior discussion of the technique and the potential complications of nerve damage and local anaesthetics effects.

2.6.3. Catheter insertion and consequent injection of local anaesthetic should be performed in a suitable environment where an aseptic technique can be performed and where there are adequate resuscitation facilities.

2.6.4. The choice of the catheter rests with the operator – nerve stimulator/catheter specific sets are available, but the use of epidural catheters is acceptable.

2.6.5. Aseptic technique should include hand washing, sterile gloves, face mask and an appropriate skin cleansing preparation and sterile drapes around the injection site.

2.6.6. A trained assistant should be present to help with the trolley preparation, location of nerve and consequent insertion.

2.6.7. Where chlorhexidine 0.5% is used drying time should be allowed prior to insertion of any needle or catheter (1-2 minutes).

2.6.8. Insertion of catheters may have less associated risks if performed in the awake patient although, many patients prefer to be asleep for the procedure. They should be made aware of the potentially slightly increased risk of detection of neural damage.

2.6.9. The catheter should be inserted to a reasonable depth percutaneously prior to being secured to minimise movement – current use of the ‘lock it’ device and covered by a clear dressing allows visibility of insertion site

2.6.10. Where long term use is required or placement is in a mobile area tunnelling the catheter superficially may be considered.

2.6.11. Operators should be aware of local infection guidelines (including the use of antibiotics in special circumstances)

2.6.12. Operators should be aware of potential hazards in respect of insertion and removal in patients on anticoagulants or with impaired clotting.

2.6.13. Operators should be aware of the monitoring guidelines and be confident that the ward has adequate staff prior to the commencement of the procedure.
2.7. Prescribing Guidelines

2.7.1. Prior to surgery and the initiation of the infusion the operator will consider the suitability of the patient for specific infusions based on:

- Age and physiology
- Risk versus benefit
- Effectiveness of analgesia with respect to type of surgery
- Specific contraindications

2.7.2. All patients must have iv access maintained for the duration of the infusion and the infusion device and catheter must be clearly labelled ‘Local Infusion’ and the site to which it is attached.

2.7.3. Infusions should be prepared in a sterile environment or pre-prepared where possible.

2.7.4. There are limitations on the drugs and concentrations which should be infused to ensure decreased risk of local anaesthetic toxicity.

2.7.5. All drug infusions should take account of patient weight and the recommended safe dose in mg/kg as per BNF.

2.7.6. When prescribing the local anaesthetic drug the following information should be provided:

- Name of drug
- Site of catheter where drug is to be infused
- Concentration of solution being infused in % and mg/ml
- Hourly rate or frequency of bolus of required
- Maximum dose not to be exceeded over a 24 hour period – in ml and total no of mg

2.7.7. Current drug used at RCHT for local anaesthetic infusion is bupivacaine which is available in a pre-prepared bag at a concentration of 0.167% (i.e. 1.67 mg per ml).

2.7.8. Sterile 10 ml ampoules of bupivacaine are available in concentrations of 0.25% and 0.5%. (i.e. 2.5 and 5 mg /ml respectively)

2.7.9. The upper recommended dose of bupivacaine as an initial loading dose is 1.5 – 2 mg/kg

2.7.10. Maintenance doses as hourly rates of infusion should not normally exceed 0.5mg/kg or 2mg/kg at 4-6 hourly top ups.

2.7.11. BNF recommend a total dose per 24 hours period of 400mg. This equates to:

- 80 ml/24 hours of 0.5 % maximum rate 3ml/hr
- 160 ml/24 hours of 0.25% maximum rate 6ml/hr
2.7.12. Dilute solutions are found to be effective for analgesia and concentrations over 0.25% are not usually necessary.

2.7.13. Very large volumes could cause swelling and catheter displacement and leakage in more superficially placed catheters.

2.7.14. Infusion rates should rarely be over 5 ml per hour. If a larger volume is required the concentration should be decreased accordingly.

2.7.15. For specific operations or conditions, there may be bilateral catheters inserted e.g. rectus sheath blocks for a laparotomy; bilateral mastectomies or hernias, when care should be taken to ensure that the sum of each catheter infusate does not exceed the total hourly recommended amount.

2.7.16. A range of rate of infusion should be prescribed together with the necessary supportive therapy such as oxygen according to the Trust guidelines and potential fluid bolus should hypotension occur.

2.7.17. IV, IM or oral opioids may be simultaneously administered without additional risks in line with RCHT policies for opiate administration.

2.7.18. The pain scores should be 0 or 1 on movement and 0 at rest.

2.8. **Local Anaesthetic Toxicity**

2.8.1. Local anaesthetics, if prescribed correctly, will rarely cause toxic effects however if there is direct infusion into a vein or the solution is absorbed rapidly or a patient is unduly sensitive then the signs and symptoms of toxicity may occur.

2.8.2. Signs are classified as per MEWS chart with relevant treatment guide.

2.8.3. All staff working with local anaesthetic infusions should be aware of the signs and treatments of LA toxicity. If not acted upon in the early stages then respiratory and cardiac arrest can occur which is very difficult to reverse because the ‘acidotic’ arrest state causes more of the drug to enter the cells and worsen the situation.

2.8.4. Whilst treating the signs and symptoms symptomatically there are also directions for Intralipid Infusion treatment if the condition deteriorates.

2.8.5. All sites where local anaesthetics are used should have an Intralipid Rescue Pack and all staff involved in the care of local anaesthetic infusions should have knowledge of the location and use of the pack.

2.8.6. The infusion rate should be regularly checked and compared with the prescription to ensure correct rate is running and the site of infusion checked for leakage.
Table 4. Signs and symptoms of Local anaesthetic Toxicity (as shown on the MEWS chart)

<table>
<thead>
<tr>
<th>score</th>
<th>signs</th>
<th>action</th>
</tr>
</thead>
<tbody>
<tr>
<td>0</td>
<td>normal</td>
<td>observe</td>
</tr>
<tr>
<td>1</td>
<td>Lightheadedness, lip tingling Tinnitus or</td>
<td>Stop LA infusion, Attach ECG monitor</td>
</tr>
<tr>
<td></td>
<td>metallic taste in mouth</td>
<td>Maintain oxygenation and BP</td>
</tr>
<tr>
<td></td>
<td></td>
<td>If symptoms deteriorate call for help</td>
</tr>
<tr>
<td>2</td>
<td>Visual disturbance Muscle twitching,</td>
<td>Stop LA infusion, Attach ECG monitor</td>
</tr>
<tr>
<td></td>
<td>convulsions</td>
<td>Maintain oxygenation and BP</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Call for help, give fluids for hypotension</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Treat convulsions with diazepam</td>
</tr>
<tr>
<td>3</td>
<td>Cardiac arrhythmias, hypotension Respiratory and cardiac arrest</td>
<td>As above and treat cardiac arrest with chest compressions and advanced life support.</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Treat toxicity with Intralipid protocol</td>
</tr>
</tbody>
</table>

2.8.7. Oxygen should be given immediately and supportive treatment commenced with fluid.

2.8.8. Call for medical help and if severe the intralipid protocol should be commenced.

Table 5. Intralipid Rescue

2.8.9. Treatment of cardiac arrest with intralipid 20% emulsion: (approximate doses are given in red for a 70-kg patient)

- Give an intravenous bolus injection of Intralipid® 20% 1.5 ml.kg-1 over 1 min
  - Give a bolus of 100 ml
- Continue CPR
- Start an intravenous infusion of Intralipid® 20% at 0.25 ml.kg-1.min-1
  - Give at a rate of 400 ml over 20 min
- Repeat the bolus injection twice at 5 min intervals if an adequate circulation has not been restored
  - Give two further boluses of 100 ml at 5 min intervals
- After another 5 min, increase the rate to 0.5 ml.kg-1.min-1 if an adequate circulation has not been restored
  - Give at a rate of 400 ml over 10 min
- Continue infusion until a stable and adequate circulation has been restored
  - Total dose 12ml/Kg – 840ml. (Ref: AAGBI 2007)
Table 6. Cardiac Arrest Treatment with Intralipid - Dose per Kg

<table>
<thead>
<tr>
<th>Intralipid 20%</th>
<th>1.5ml/Kg over 1 minute</th>
</tr>
</thead>
<tbody>
<tr>
<td>Immediate follow up infusion</td>
<td>15ml/kg/min</td>
</tr>
<tr>
<td>Continue chest compression to circulate lipid</td>
<td></td>
</tr>
<tr>
<td>Repeat bolus every 3-5 mins</td>
<td>total dose: 3ml/kg</td>
</tr>
<tr>
<td>Continue infusion until haemodynamic stability restored</td>
<td>Increase rate to 30ml/kg if hypotension or unstable</td>
</tr>
<tr>
<td>Maximum total daily dose</td>
<td>12ml/kg</td>
</tr>
</tbody>
</table>

2.9. Local Anaesthetic infusion Devices

Local anaesthetic can be delivered via a catheter using a variety of devices:

- Specific Infusion Pump with a variety of protocols (for indefinite time period)
- Disposable elastomeric pump with pre-determined infusion rate (for up to 48 hours)
- Bolus dose administration by medical or nursing staff.

All devices and catheters are clearly labelled and the devices are kept exclusively for local anaesthetic use. They must be clearly different from devices used for epidural and intravenous infusion.

2.9.1. McKinley Infusion Pump

This is a specific pump to deliver the agreed preset protocols of LA infusions over a variety of mixes which will include patient controlled programme for additional bolus doses if required.

Given the small number of pumps and infusion used the baseline infusion consists of 0.167% Bupivicaine 250 ml which is available premixed from pharmacy.

The current 0.167% bupivacaine can be delivered up to 10 ml per hour as a continuous infusion, alternatively as a 5-6 ml/hr and a 3-4ml bolus if required hourly.

More dilute infusions may be required and these could be requested from pharmacy to ensure that they are mixed in a sterile environment ideally only premixed infusions should be used.

In an emergency when pre prepared solution is not available, bupivacaine can be withdrawn and local saline 0.9% introduced to decrease the concentration. All calculations should be checked by 2 qualified practitioners to ensure that there are no drug errors and calculations entered in the notes and clearly noted on the prescription chart.
Withdrawal of drug and consequent dilution must be performed using aseptic technique as per RCHT guidelines for drawing up injections:

An example using 0.167% bupivacaine in a 250ml bag.

**For a 0.1% solution withdraw 100ml of bupivacaine and replace with 100 ml saline**

<table>
<thead>
<tr>
<th>Initial mg in 250 ml of 0.167% bupivacaine</th>
<th>= 417.5mg (1.67mg/ml)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Required mg to produce 0.1% bupivacaine</td>
<td>= 250mg (1mg/ml)</td>
</tr>
<tr>
<td>Amount mg to be withdrawn to leave 250 mg</td>
<td>= 417.5 - 250 = 167.5mg</td>
</tr>
<tr>
<td>Amount of solution containing 167.5mg</td>
<td>= 167.5/1.675 = 100 ml</td>
</tr>
<tr>
<td>Withdraw 100ml of 0.167% bupivacaine and replace with 100ml 0.9% saline to produce 0.1% bupivacaine in a 250 ml bag</td>
<td></td>
</tr>
</tbody>
</table>

The use of the while Mckinley pumps should be restricted to one sided analgesia and should only be used for dilute infusions of local anaesthetic.

There will be 3 protocols for infusion:

- 0.25% bupivacaine - special order from pharmacy for infusion rates 0 – 5 ml per hour
- 0.167% bupivacaine – 250 ml bag, available from pharmacy, for infusion rates of 0 – 10m/hr
- 0.1% bupivacaine – 250 ml (prepared as above) for infusion rates of 0 – 15 ml/hr

The weight of the patient should be taken into consideration before prescribing the rate

The infusion should be clearly labelled ‘Local Anaesthetic’ as should the catheter delivering the infusate

The Mckinley pump will have a facility for an additional bolus which will be security coded enabling only anaesthetists, recovery nurses and pain nurses to access in a similar way to epidural pumps.

All bolus should be given under close monitoring conditions.

It is anticipated that these pumps will be used for:

- Infusions into specific nerves or plexi such as the femoral nerve or brachial plexus
- Infusions into specific areas such as sub pectoral post mastectomy
- Infusions subcutaneously into wounds

It would be expected that staff familiar in the use of the McKinley epidural pump would be able to operate the local infusion device, but, training by the pain nurses would be given to ensure knowledge is up to date.
It is expected that all staff familiar with the care of local anaesthetic infusions via the epidural pump will be sufficiently trained to care for patients receiving a more peripheral local anaesthetic infusion.

2.9.2. **The Pain Buster Infusion Device**

This consists of an elastomeric ball and delivery tubing, which delivers a predetermined rate of infusionate, depending on the size and initial volume of the balloon. The current sizes used are 100 and 250 ml delivering respectively infusion rates of 2ml/hour and 5ml/hour over a 48 hour period.

It is connected to the catheter which has been placed usually by the surgeon at the time of operation and tunnelled through the skin with a completely aseptic technique and fixed using a 'lock-it' device and clear dressing.

The balloon is filled according to the manufacturers’ guidelines using an aseptic technique by the scrub nurse at the time of surgery. Elastomeric devices must only be filled by those Health Care Professionals who have received appropriate training.

The local anaesthetic mix should be checked by the anaesthetist and the scrub nurse prior to insertion and the ampoules or solution form a larger bag checked by the surgeon prior to the connection of the balloon to the catheter.

It is usual to administer small bolus dose of the same solution to prime the line.

Where the smaller balloon volume is used a higher concentration of local anaesthetic may be used e.g. 0.5% bupivacaine at 2ml/hour although 0.375% (an equal mix of 0.5 and 0.25%) or 0.25% may be sufficient.

The pain buster device may be used where patient mobility is required or in the absence of local anaesthetic specific pump availability.

Examples where the use is indicated include:

- Joint surgery – where no drain is present
- Relatively Superficial body surface surgery e.g. breast, hernias
- Bilateral Rectus Sheath Blocks
- Nerve plexus infusions

**N.B.** The use of a specific infusion device such as this ensures that there is no confusion with other mechanical infusion pumps being used on the patient and serves as an additional safety measure for this technique.

The device must be clearly labelled as should the catheter leading to the balloon.

Once the catheter is secured to the skin, the balloon is attached to the dressing by the clip.

The local anaesthetic should be clearly prescribed and the addition, if any, of other drugs such as anti-inflammatory drugs into the mix clarified.
This is a single use only device and it is not expected that the device will be refilled and reused after 48 hours once it is deflated.

Table 7. Suggested Drug Regimes using Elastomeric devices (eg Pain Buster)

<table>
<thead>
<tr>
<th>Surgical procedure/site</th>
<th>Drug/concentration</th>
<th>Infusion Rate</th>
</tr>
</thead>
<tbody>
<tr>
<td>Joint surgery (where no drain)</td>
<td>Bupivacaine 0.25% or 0.5% Potential addition of ketorolac 60mg if indicated</td>
<td>2ml/hour</td>
</tr>
<tr>
<td>Breast surgery/superficial body surgery</td>
<td>Bupivacaine 0.25% or 0.5%</td>
<td>2ml/hr</td>
</tr>
<tr>
<td><em>if more than one pain buster is to be used then 0.25% should be used to minimise the total dose in the 100ml balloons</em></td>
<td>Bupivacaine 0.25% or 0.167% from infusate bag or 0.125% if more than one of larger volume pain buster used</td>
<td>2ml or 5ml/hour</td>
</tr>
<tr>
<td>Breast surgery/superficial body surgery</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Plexus blocks</td>
<td>Bupivacaine 0.25% or 0.167%</td>
<td>2ml/hr or 5ml/hr</td>
</tr>
</tbody>
</table>

The anaesthetist should be consulted at the time of insertion as to the appropriateness of the dose and all precautions should be taken to ensure the patient is monitored post operatively for signs of local anaesthesia toxicity.

If there is leakage from catheter site or balloon seek advice from the pain team.

2.10. Observations and Monitoring

All patients receiving an infusion of local anaesthetic should be monitored for sensation, motor power and signs of toxicity and the observations recorded with other vital signs on the MEWS chart.

2.10.1. General Observations

Nursing staff must be aware of the potential side effects and complications of local anaesthesia and their management. It is assumed that nurses with training for care of epidurals and knowledge of the side effects and potential signs of toxicity will be able to care for patients with local infusions.

Timely observations are necessary for the safe delivery of this method of analgesia.

All observations will be recorded on the RCHT MEWS chart which combines the
regular observations of vital functions (RR, BP, HR, oxygen saturation and urine output) with those more specific parameters and scores necessary for safe and effective local analgesia delivery:

Pain at rest and movement, sedation, sensation, power and signs of LA toxicity.

Scoring criteria are at the bottom of the MEWS observation chart and those scores within red area would indicate that there are potential side effects occurring and the algorithms on the reverse of the form should be referred to.

Observations should be more frequent in the first 6 hours or if the rate of infusion is changed – frequency of observations required are on the reverse of the MEWS chart.

The rate of infusion should be recorded with every observation.

General observations when local anaesthetic technique is not accompanied by strong opiates

Table 8 – Necessary frequency of observations

<table>
<thead>
<tr>
<th>Monitoring parameter</th>
<th>1st hour</th>
<th>Following 2 hours</th>
<th>thereafter</th>
</tr>
</thead>
<tbody>
<tr>
<td>Respiratory Rate</td>
<td>Every 15 mins</td>
<td>hrly</td>
<td>2Hrly for 24 hrs</td>
</tr>
<tr>
<td>Blood Pressure</td>
<td>Every 15 mins</td>
<td>hrly</td>
<td>2Hrly for 24 hrs</td>
</tr>
<tr>
<td>Heart Rate/sats</td>
<td>Every 15 mins</td>
<td>hrly</td>
<td>2Hrly for 24 hrs</td>
</tr>
<tr>
<td>Pain score at rest</td>
<td>Every 15 mins</td>
<td>hrly</td>
<td>2Hrly for 24 hrs</td>
</tr>
<tr>
<td>Pain score on movement</td>
<td>Every 15 mins</td>
<td>hrly</td>
<td>2Hrly for 24 hrs</td>
</tr>
<tr>
<td>Sedation</td>
<td>Every 15 mins</td>
<td>hrly</td>
<td>2Hrly for 24 hrs</td>
</tr>
<tr>
<td>Motor power</td>
<td>once</td>
<td>2 hrly</td>
<td>4Hrly for 24 hrs</td>
</tr>
<tr>
<td>sensation</td>
<td>With pain scores</td>
<td>2 hrly</td>
<td></td>
</tr>
<tr>
<td>LA toxicity</td>
<td>hrly</td>
<td>2 hrly</td>
<td>4 hrly</td>
</tr>
</tbody>
</table>

*If patient is stable and infusion rate remains unchanged monitor 4 hrly after this, if patient is in pain, the rate of infusion changes or the patient is in labile condition the continue with observations more frequently.

2.10.2. **Respiratory Rate**

Regular monitoring of the respiratory rate should accompany the monitoring of the use of local anaesthetic particularly if it is being used in conjunction with strong opiates e.g. with a PCA as a multimodal approach when observations should be as for those patients with a PCA and epidural infusions.
Table 9. Necessary frequency of observations with LA infusion and parenteral opiates.

<table>
<thead>
<tr>
<th>Monitoring parameter</th>
<th>1st hour</th>
<th>Following 2 hours</th>
<th>thereafter</th>
</tr>
</thead>
<tbody>
<tr>
<td>Respiratory Rate</td>
<td>Every 15 mins</td>
<td>Every 30 mins</td>
<td>Hrly for 24 hrs</td>
</tr>
<tr>
<td>Blood Pressure</td>
<td>Every 15 mins</td>
<td>Every 30 mins</td>
<td>Hrly for 12 hrs, then 2hrly if stab</td>
</tr>
<tr>
<td>Heart Rate/sats</td>
<td>Every 15 mins</td>
<td>Every 30 mins</td>
<td>Hrly for 12 hrs then 2hrly if stab</td>
</tr>
<tr>
<td>Pain score at rest</td>
<td>Every 15 mins</td>
<td>Every 30 mins</td>
<td>Hrly for 24 hrs</td>
</tr>
<tr>
<td>Pain score on movement</td>
<td>Every 15 mins</td>
<td>Every 30 mins</td>
<td>Hrly for 24 hrs</td>
</tr>
<tr>
<td>Sedation</td>
<td>Every 15 mins</td>
<td>Every 30 mins</td>
<td>Hrly for 24 hrs</td>
</tr>
<tr>
<td>Motor power/sensation</td>
<td>一次</td>
<td>*Every hr</td>
<td>4-6 hrly for 24 hrs</td>
</tr>
<tr>
<td>LA toxicity</td>
<td>hrly</td>
<td>2 hrly</td>
<td>4-6 hrly</td>
</tr>
</tbody>
</table>

If respiratory rate falls below 8 when local analgesia is used in conjunction with a PCA, give oxygen and follow algorithm on MEWS chart.

The decrease in respiratory rate is more likely to be due to the opiates if no other signs of toxicity are detected and the PCA should be temporarily stopped and observations increased.

Table 10. Recommended action for decreased respiratory rate with LA infusion and PCA.

<table>
<thead>
<tr>
<th>Resp Rate</th>
<th>Action to take</th>
</tr>
</thead>
<tbody>
<tr>
<td>≤ 10</td>
<td>Increase frequency of Observations</td>
</tr>
<tr>
<td>≤ 8</td>
<td>Stop PCA infusion, give oxygen, observe and consider naloxone</td>
</tr>
<tr>
<td>≤ 5</td>
<td>As above and give naloxone immediately and stop LA infusions</td>
</tr>
</tbody>
</table>

Table 11 – Naloxone mixture

400 microgms of Naloxone should be diluted in 3ml of 0.9%NaCl  
Give in 1 ml increments every 5 mins  
Give until resp rate increases to 8 and sedation score greater than 2  
Seek medical advice if resp rate remains low

2.10.3. Management of hypotension

Sympathetic blockade by local anaesthetic can sometimes occur, particularly when catheter is in close proximity to sympathetic nerves or is causing vasodilation.

Other causes for decrease in blood pressure should be excluded before assuming they are due to the local infusion.
Systolic blood pressure should be greater than 90mmHg systolic unless otherwise stated. Hypertensive patients may require a higher baseline to maintain organ function – particularly urine output. It would be expected that the anaesthetist involved in the catheter insertion would state acceptable parameters for systolic pressure (level and time period) after which intervention would be required in terms of fluid bolus as per chart.

Table 12. Recommended Action for hypotension

<table>
<thead>
<tr>
<th>Consciousness/saturation</th>
<th>action</th>
</tr>
</thead>
</table>
| Alert                   | Lie patient flat  
Normal saturation       | Give oxygen 8 litre/min  
Give plasma expander – 250ml of crystalloid  
Do not put patient head down only if LA infusion above waist. |
| Drowsy                  | Lie patient flat  
Saturation less than 92% | Do not put head down if LA infusion above waist  
Give oxygen  
Give plasma expander – up to 500ml  
Call for medical help  
Give ephedrine 3-9mg iv |

Following the administration of a bolus dose of fluid the blood pressure must be observed at 5 min intervals until increasing or for 30 mins after stable.

2.10.4. Heart Rate

Monitor heart rate as per requirements along with BP

- If there is a bradycardia with normal BP check level at which patient is numb  
- Call for medical help if rate 10-20 below normal base rate  
- Administer either ephedrine (to increase pulse and BP) 3-6 mg bolus or  
- Give Atropine 600microgm for persistent bradycardia  
- If heart rate falls below 40/min or patient is compromised put out urgent response bleep or crash call.

2.10.5. Pain Score and sensation

Pain scores and sensation should be recorded and documented regularly with every observation when patient is awake – both at rest and on movement. If patient is asleep then this may be recorded but not for more than 3 successive observations.

If pain score is higher than 1 adjust rate of infusion to maximum, ensure multimodal analgesia is given and if pain continues contact medical staff for advice
N.B. Strong opiates may be given with LA infusions

2.10.6. **Sedation**

If Sedation score is greater than 2 then medical help should be sought.

2.10.7. **Nausea Score**

Patients should be regularly checked for feelings of nausea and vomiting and all should have appropriate anti emetics prescribed as per RCHT guidelines.

**2.11. Catheter Management**

2.11.1. **Catheter Site Care**

Catheters are not sutured in place and therefore may easily fall out.

Dressing changes to the catheter exit site should only be carried out by the Acute Pain team or an anaesthetist when it is necessary.

The aims are to ensure sterility and security of the system and prevent entry of bacteria into the potential space and allow visibility of the catheter.

If changing the dressing all sterile precautions should be taken in accordance with RCHT policy.

The catheter is fixed with a ‘lockit clip’; removal of this clip would necessitate disconnection of the catheter and its threading through the lock it port – this should only be undertaken by trained acute pain nurses and anaesthetists as there is a high risk of catheter dislodgement.

If the old dressing needs to be removed the ‘lock it’ should be retained and covered with a clear adherent dressing.

The dressing should be smooth and there should be no kinks in the catheter.

It is the nurses’ responsibility to check the catheter site regularly (eg twice daily) to check the dressing is secure and remains covering the catheter.

If the dressing is insecure or there is a leak of fluid, it should be secured with additional tape and pad.

2.11.2. **Catheter Line and Filter**

Nursing management of the line and filter should aim to prevent disconnection of the filter from the catheter and maintain the integrity of the system as well as promoting comfort at the filter site.

Effective management of the catheter line is essential in preventing any pulling of the actual catheter and its potential dislodgement or disconnection.
If the catheter becomes disconnected or dislodged it should not usually be replaced and will usually require removal which can be undertaken by any competent health professional trained in aseptic technique. (see removal) If there is reluctance to remove the catheter and further advice is needed:

- Wrap the filter and catheter in gauze
- Stop the infusion
- Contact the acute pain team or the anaesthetist on call.

2.11.3. Removal of Catheters

Local anaesthetic infusion catheters can be removed by registered nurses who have been trained and assessed as competent in aseptic technique.

Catheters have not been fixed within the space and once the 'lock-it' is removed the catheter should be freed with minimal pressure.

If the catheter feels as if there is some resistance do not force and contact the acute pain team or the anaesthetist on call for advice.

Check the catheter after removal to ensure the entire length has been removed and that a rounded tip is present.

Catheter removal should not occur unless the patients clotting is normal or within an accepted range - INR≤1.5 and a platelet count of ≥ 80,000.

It would be expected that if the bleeding history is negative that routine coagulation screening prior to removal would not be required. (FBC prior to surgery to confirm platelet count would be acceptable)

The catheter should be removed taking into consideration the timing of any prophylactic anticoagulation. Catheter removal early in the day will ensure sufficient time to monitor patient during working hours for any signs of haematoma at the site of entry and exit.

Procedure for Removal of Catheter

- Wash hands as per RCHT hand hygiene policy
- Gather equipment – a small dressing and gloves
- Explain the procedure to the patient
- Position the patient comfortably where access to the catheter is easiest
- Remove the catheter slowly
- Observe the site for leakage, fluid or signs of infection.
Check catheter to ensure tip is complete – if not contact Acute Pain Team for advice.

Clean with NaCl 0.9% and apply adhesive dressing over site

Check for any signs of infection such as pus or redness at site of entry – if there are any signs save the catheter tip for Culture and sensitivity and swab the insertion site.

2.12. Anticoagulants and Local Infusion Catheters

Consideration must be paid to the patients’ anticoagulation status prior to catheter removal and should be in line with RCHT anticoagulation/DVT prophylaxis policy.

It is unlikely that removal of catheter will cause bleeding and if this is the case then local pressure should be applied for 5 minutes or until it has decreased, however the following precautions may be taken.

2.12.1. IV Heparin

There may be increased incidence of haematoma if patient is receiving iv heparin particularly if the therapeutic ratio is ≥2 – 2.5

Catheters placed prior to heparin administration should not present a problem.

If the patient remains on heparin and it is considered essential to place a catheter for LA infusion then Heparin should be stopped 2-4 hours pre procedure (insertion and removal) and checking an urgent APTT ratio 2 hours prior to procedure.

If required the IV heparin infusion can be restarted at least 1 hour after catheter insertion.

Patients receiving peri operative heparinsation, such as those undergoing vascular surgery, should have the insertion of catheter prior to heparinisation, and not have the catheter removed for at least 12hours post operatively after a coagulation check is normal.

2.12.2. Treatment Dose Dalteparin

Careful consideration as to the need for indwelling LA infusions should occur prior to this method of analgesia being selected when the following precautions are suggested should be taken:

Wait at least 24 hours after a dose of dalteparin 100 units/Kg s/c before insertion or removal of catheter.

If the patient has received a larger dose then avoid regional techniques.
Prophylactic dose eg 5000u s/c:

- Wait 6 hrs after catheter insertion / removal before administering;
- Wait 12 hours after administering before inserting/removing catheter.

Treatment dose eg 100units/kg sc

- Wait 6 hours after catheter insertion / removal before administering.
- Wait 24 hours after administering before catheter insertion/removal.
- Then continue with therapeutic dose dalteparin approximately 12 hours after last prophylactic dose.

2.12.3. **Warfarin**

The INR should be ≤ 1.5 - 2.0 before catheter is inserted or removed.

If a local infusion catheter inadvertently falls/is removed whilst a patient is anticoagulated there may be an increased risk of haematoma and a pressure dressing to the area should be applied.

2.13. **Discontinuing local anaesthetic infusion.**

Removal of catheter usually occurs after 48 hours. The risk of infection increases after with time.

This risk may increase in immunocompromised and diabetic patients.

There may be occasions when there needs to be more prolonged analgesia. The catheter could stay in situ provided there is no leakage or sign of inflammation.

Anticipated long term LA analgesia should have a tunnelled catheter inserted and advice of the acute pain team or pain consultants may be needed.

**Factors to Consider Prior to Discontinuation**

2.13.1. **Severity of pain expected.**

- Patient’s ability to tolerate other routes of analgesia.
- It would be anticipated that this has been part of a multimodal analgesic approach therefore other analgesia has probably been administered, however if this is not the case, then analgesia must be prescribed before the infusion is stopped. Analgesia should be prescribed as regular as well as prn.
• Regular pain assessment should continue to ensure patient’s pain control is well managed

2.13.2. Patient preference.

• Patients or carers wishes should be taken into consideration. If a patient requests they no longer wish to receive local anaesthetic infusions then alternative options should be discussed ensuring the patient is fully informed prior to making a choice.

3. Monitoring compliance and effectiveness

<table>
<thead>
<tr>
<th>Element to be monitored</th>
<th>Adherence to RCHT guidelines</th>
</tr>
</thead>
<tbody>
<tr>
<td>Lead</td>
<td>Acute pain lead</td>
</tr>
<tr>
<td>Tool</td>
<td>Regular audits and regular surveillance will occur throughout the year and reported at the regular acute pain meetings and appropriate governance meetings</td>
</tr>
<tr>
<td>Frequency</td>
<td>Yearly audit as required by NPSA guidelines will be undertaken.</td>
</tr>
<tr>
<td>Reporting arrangements</td>
<td>The committee reviewing the cases will be the anaesthesia directorate. Cases will be discussed at audit meetings and the details will be recorded in the minutes.</td>
</tr>
<tr>
<td>Acting on recommendations and Lead(s)</td>
<td>See above</td>
</tr>
<tr>
<td>Change in practice and lessons to be shared</td>
<td>Required changes to practice will be identified and implemented within a month. A lead member of the team will be identified to take each change forward where appropriate. Lessons will be shared with all the relevant stakeholders</td>
</tr>
</tbody>
</table>

4. Equality and Diversity

4.2. This document complies with the Royal Cornwall Hospitals NHS Trust service Equality and Diversity statement which can be found in the 'Equality, Diversity & Human Rights Policy' or the Equality and Diversity website.

4.3. Equality Impact Assessment

The Initial Equality Impact Assessment Screening Form is at Appendix 2.
Appendix 1. Governance Information

<table>
<thead>
<tr>
<th>Document Title</th>
<th>Continuous Local Anaesthetic Infusions for Post Operative Pain Relief</th>
</tr>
</thead>
<tbody>
<tr>
<td>Date Issued/Approved:</td>
<td>24 Oct 11</td>
</tr>
<tr>
<td>Date Valid From:</td>
<td>Feb 15</td>
</tr>
<tr>
<td>Date Valid To:</td>
<td>Feb 18</td>
</tr>
</tbody>
</table>
| Directorate / Department responsible (author/owner): | Anaesthesia and Theatre Directorate Acute Pain Team  
Original Author: Dr Anne Dingwall  
Current owner: Dr Nicholas Marshall |
| Contact details: | 01872 253392 |
| Brief summary of contents | This document outlines the potential and actual use of Local Anaesthetic with in RCHT and the precautions and care required. |
| Suggested Keywords: | Pain buster, Nerve infusion, Nerve Block, Local Anaesthesia, Bupivacaine |
| Target Audience | RCHT PCH CFT KCCG |
| Executive Director responsible for Policy: | Dr Rob Parry, Medical Director |
| Date revised: | Feb 2015 |
| This document replaces (exact title of previous version): | Continuous Local Anaesthetic Infusions for Post Operative Pain Relief |
| Approval route (names of committees)/consultation: | Anaesthetic Department |
| Divisional Manager confirming approval processes | Divisional Director: Dr Will Fox  
Divisional Manager: Mr Duncan Bliss |
| Name and Post Title of additional signatories | Speciality leads of General anaesthesia, critical care and pain |
| Signature of Executive Director giving approval | {Original Copy Signed} |
| Publication Location (refer to Policy on Policies – Approvals and Ratification): | Internet & Intranet  
Intranet Only |
| Document Library Folder/Sub Folder | Clinical / Anaesthesia |
Links to key external standards
AAGBI Royal College of Anaesthetists
ESRA British Pain Society

Related Documents:
None

Training Need Identified?
No

Version Control Table

<table>
<thead>
<tr>
<th>Date</th>
<th>Version No</th>
<th>Summary of Changes</th>
<th>Changes Made by (Name and Job Title)</th>
</tr>
</thead>
<tbody>
<tr>
<td>07 Jan 12</td>
<td>V1.0</td>
<td>Initial Issue</td>
<td>Dr Anne Dingwall Consultant Anaesthetist</td>
</tr>
<tr>
<td>09 Feb 15</td>
<td>V2.0</td>
<td>Updated guideline. Addition of Monitoring Compliance table.</td>
<td>Dr Juan Graterol Consultant Anesthetist</td>
</tr>
<tr>
<td>09 Feb 15</td>
<td>V2.1</td>
<td>Governance information moved to an appendix. EIA updated. Governance information amended to align with format of Document Manager Upload</td>
<td>Dr Juan Graterol Consultant Anesthetist</td>
</tr>
<tr>
<td>09 Feb 15</td>
<td>V2.2</td>
<td>Updated governance information table to include KCCG.</td>
<td>Dr Juan Graterol Consultant Anesthetist</td>
</tr>
</tbody>
</table>

All or part of this document can be released under the Freedom of Information Act 2000

This document is to be retained for 10 years from the date of expiry.

This document is only valid on the day of printing.

Controlled Document
This document has been created following the Royal Cornwall Hospitals NHS Trust Policy on Document Production. It should not be altered in any way without the express permission of the author or their Line Manager.
## Appendix 2. Initial Equality Impact Assessment Form

<table>
<thead>
<tr>
<th>Name of Name of the strategy / policy / proposal / service function to be assessed (hereafter referred to as policy) (Provide brief description): Continuous Local Anaesthetic Infusions for Post Operative Pain Relief</th>
<th>Is this a new or existing Policy? Existing</th>
</tr>
</thead>
<tbody>
<tr>
<td>Directorate and service area: Theatres/Anaesthesia</td>
<td></td>
</tr>
<tr>
<td>Name of individual completing assessment: Dr Juan Graterol</td>
<td>Telephone: 01872 253392</td>
</tr>
</tbody>
</table>

1. **Policy Aim***
   - Who is the strategy / policy / proposal / service function aimed at?
   - To provide guidelines for those caring for a patient with a local anaesthesia nerve infusion. Doctors and Nurses.

2. **Policy Objectives***
   - To provide information for the setup and safe use of a local anaesthesia nerve infusion in the ward environment.

3. **Policy – intended Outcomes***
   - Safe and appropriate use of local anaesthetic infusions on the ward.

4. **How will you measure the outcome?***
   - Monitoring through audit and case discussion at governance meetings.

5. **Who is intended to benefit from the policy?***
   - Patients

6a) **Is consultation required with the workforce, equality groups, local interest groups etc. around this policy?***
   - No

   b) **If yes, have these *groups been consulted?***

   C). Please list any groups who have been consulted about this procedure.

### 7. The Impact

Please complete the following table.

<table>
<thead>
<tr>
<th>Equality Strands</th>
<th>Yes</th>
<th>No</th>
<th>Rationale for Assessment / Existing Evidence</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age</td>
<td></td>
<td>X</td>
<td></td>
</tr>
<tr>
<td>Category</td>
<td>X</td>
<td></td>
<td></td>
</tr>
<tr>
<td>----------------------------------------------</td>
<td>---</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Sex (male, female, transgender / gender reassignment)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Race / Ethnic communities / groups</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Disability - learning disability, physical disability, sensory impairment and mental health problems</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Religion / other beliefs</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Marriage and civil partnership</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pregnancy and maternity</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Sexual Orientation, Bisexual, Gay, heterosexual, Lesbian</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

You will need to continue to a full Equality Impact Assessment if the following have been highlighted:

- You have ticked “Yes” in any column above and
- No consultation or evidence of there being consultation- this excludes any policies which have been identified as not requiring consultation. **or**
- Major service redesign or development

8. Please indicate if a full equality analysis is recommended. [ ] Yes [x] No

9. If you are not recommending a Full Impact assessment please explain why. Not required

Signature of policy developer / lead manager / director
Dr Juan Graterol
Date of completion and submission: 30/06/2015

Names and signatures of members carrying out the Screening Assessment
1. 
2.

Keep one copy and send a copy to the Human Rights, Equality and Inclusion Lead, c/o Royal Cornwall Hospitals NHS Trust, Human Resources Department, Knowledge Spa, Truro, Cornwall, TR1 3HD

A summary of the results will be published on the Trust’s web site.

Signed ______________

Date ______________

Clinical Guideline Template
Appendix 3. Identification and Management of Local Anaesthetic Toxicity

Local and regional nerve blocks allow patients to be pain free following surgery and mean that less strong painkillers are necessary.

Local anaesthetic lasts for a limited time period, therefore to ensure that the patient remains comfortable further local anaesthetic should be given either via a continuous infusion or regular top up bolus doses.

Very rarely there may be rapid absorption into the blood stream when signs of toxicity may occur.

This is very rare but it is very important that the signs are recognised

**IT IS IMPORTANT THAT ALL PATIENTS RECEIVING A LOCAL ANAESTHETIC INFUSION OR BOLUS ARE REGULARLY MONITORED FOR EARLY DETECTION OF TOXICITY**
If symptoms are group 2 or 3

- Stop infusion of local anaesthetic, attach monitors
- Maintain oxygenation and cardiac output
- Phone for help immediately – cardiac/urgent bleep
- Treat hypotension with fluids
- Treat convulsions with diazepam
- Treat cardiac arrest with ECM and intralipid
- Treat toxicity with local intralipid protocol - rescue box available from all theatre recovery areas

Lipid Rescue
For LA induced cardiac arrest
CPR + intralipid 20%
Intralipid 20% 1.5ml/kg over 1 minute
Immediate follow up infusion – 15ml/kg/min
Continue chest compression to circulate lipid
Repeat bolus every 3-5 mins (total dose:3ml/kg)
Continue infusion until haemodynamic stability restored
Increase rate to 30ml/kg if hypotension or unstable
Maximum total daily dose: 12ml/Kg

Identify symptoms as mild: group 1

- Stop local anaesthetic infusions and observe
- Attach ecg and monitors
- Maintain oxygenation and BP
- Consult with pain team or anaesthetist on call
- If symptoms deteriorate phone for help if urgent - cardiac arrest call

ESSENTIAL MONITORING (INFUSIONS OR POST BOLUS DOSE)

Hourly BP and pulse rate and saturation levels and respiratory rate
Question patient for signs of light headedness and numbness of tongue or double vision
Look for restlessness or muscle twitching or change in level of consciousness

Signs of toxicity

Mild (1)
- restlessness/confusion
- light-headedness
- numbness of tongue and lips (lip smacking)
- tinnitus
- double vision, blurring of eyesight

Moderate (2)
- heaviness of limbs
- muscular twitching
- generalised convulsions

Severe (3)
- Cardiac arrhythmias (particularly bupivacaine)
- Hypotension
- Respiratory arrest
- Cardiac arrest

Clinical Guideline Template